Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Scholar Rock
Fierce Pharma
Novo’s Catalent plant ditched in FDA refiling of SMA drug
A recent FDA inspection of Novo's troubled Catalent site in Indiana has been classified as “Official Action Indicated.”
Angus Liu
Aug 10, 2026 10:06am
Scholar Rock's SMA drug helps Zepbound patients retain muscle
Jun 18, 2025 9:10am
Scholar Rock rocks the boat with new execs—Chutes & Ladders
May 2, 2025 8:30am
Private equity firms take over bluebird's nest—Chutes & Ladders
Feb 28, 2025 8:30am
Takeda taps Julie Kim as new CEO—Chutes & Ladders
Jan 31, 2025 8:30am
Phase 3 Scholar Rock trial hits SMA goal, sending stock up 327%
Oct 7, 2024 8:45am
